Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Autor: Cahn, PE, Cassetti, I, Losso, M, Bloch, MT, Roth, N, McMahon, J, Moore, RJ, Smith, D, Clumeck, N, Vanderkerckhove, L, Vandercam, B, Moutschen, M, Baril, J, Conway, B, Smaill, F, Smith, GHR, Rachlis, A, Walmsley, SL, Perez, C, Wolff, M, Lasso, MF, Chahin, CE, Velez, JD, Sussmann, O, Reynes, J, Katlama, C, Yazdanpanah, Y, Ferret, S, Durant, J, Duvivier, C, Poizot-Martin, I, Ajana, F, Rockstroh, JK, Faetkanheuer, G, Esser, S, Jaeger, H, Degen, O, Bickel, M, Bogner, J, Arasteh, K, Hartl, H, Stoehr, A, Rojas, EM, Arathoon, E, Gonzalez, LD, Mejia, CR, Shahar, E, Turner, D, Levy, I, Sthoeger, Z, Elinav, H, Gori, A, Monforte, A D'Arminio, Di Perri, G, Lazzarin, A, Rizzardini, G, Antinori, A, Celesia, BM, Maggiolo, F, Chow, TS, Lee, CKC, Azwa, R Iskandar Shah Raja, Mustafa, M, Oyanguren, M, Castillo, RA, Hercilla, L, Echiverri, C, Maltez, F, da Cunha, JG Saraiva, Neves, I, Teofilo, E, Serrao, R, Nagimova, F, Khaertynova, I, Orlova-Morozova, E, Voronin, E, Sotnikov, V, Yakovlev, AA, Zakharova, NG, Tsybakova, OA, Botes, ME, Mohapi, L, Kaplan, R, Rassool, MS, Arribas, JR, Gatell, JM, Negredo, E, Ortega, E, Troya, J, Berenguer, J, Aguirrebengoa, K, Antela, A, Calmy, A, Cavassini, M, Rauch, A, Stoeckle, M, Sheng, WH, Lin, HH, Tsai, HC, Changpradub, D, Avihingsanon, A, Kiertiburanakul, S, Ratanasuwan, W, Nelson, MR, Clarke, A, Ustianowski, A, Winston, A, Johnson, MA, Asmuth, DM, Cade, J, Gallant, JE, Ruane, PJ, Kumar, PN, Luque, AE, Panther, L, Tashima, KT, Ward, D, Berger, DS, Dietz, CA, Fichtenbaum, C, Gupta, S, Mullane, KM, Novak, RM, Sweet, DE, Crofoot, GE, Hagins, DP, Lewis, ST, McDonald, CK, DeJesus, E, Sloan, L, Prelutsky, DJ, Rondon, JC, Henn, S, Scarsella, AJ, Morales, JO, Ramirez, Santiago, L, Zorrilla, CD, Saag, MS, Hsiao, CB, Cahn, Pedro, Kaplan, Richard, Sax, Paul E, Squires, Kathleen, Molina, Jean-Michel, Avihingsanon, Anchalee, Ratanasuwan, Winai, Rojas, Evelyn, Rassool, Mohammed, Bloch, Mark, Vandekerckhove, Linos, Ruane, Peter, Yazdanpanah, Yazdan, Katlama, Christine, Xu, Xia, Rodgers, Anthony, East, Lilly, Wenning, Larissa, Rawlins, Sandy, Homony, Brenda, Sklar, Peter, Nguyen, Bach-Yen, Leavitt, Randi, Teppler, Hedy

Publikováno v: In The Lancet HIV November 2017 4(11):e486-e494

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.

Autor: Wohl DA; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Spinner CD; TUM School of Medicine and Health, Department of Clinical Medicine - Clinical Department for Internal Medicine II, University Medical Centre, Technical University of Munich, Munich, Germany., Flamm J; Kaiser Permanente, Sacramento, CA, USA., Hare CB; Kaiser Permanente, San Francisco, CA, USA., Doblecki-Lewis S; Division of Infectious Diseases, University of Miami, Miller School of Medicine, Miami, FL, USA., Ruane PJ; Ruane Clinical Research, Los Angeles, CA, USA., Molina JM; Infectious Diseases Department, Hopitaux Saint-Louis Lariboisière, University of Paris and INSERM U944, Paris, France., Mills A; Men's Health Foundation, Los Angeles, CA, USA., Brinson C; Central Texas Clinical Research, Austin, TX, USA., Ramgopal M; Midway Research Center, Fort Pierce, FL, USA., Clarke A; Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, UK., Crofoot G; The Crofoot Research Centre, Houston, TX, USA., Martorell C; The Research Institute, Springfield, MA, USA., Carter C; Gilead Sciences, Foster City, CA, USA. Electronic address: christoph.carter7@gilead.com., Cox S; Gilead Sciences, Foster City, CA, USA., Hojilla JC; Gilead Sciences, Foster City, CA, USA., Shao Y; Gilead Sciences, Foster City, CA, USA., Das M; Gilead Sciences, Foster City, CA, USA., Kintu A; Gilead Sciences, Foster City, CA, USA., Baeten JM; Gilead Sciences, Foster City, CA, USA., Grant RM; University of California San Francisco, San Francisco, CA, USA; San Francisco AIDS Foundation, San Francisco, CA, USA., Mounzer K; Philadelphia FIGHT Community Health Centres, Philadelphia, PA, USA., Mayer K; The Fenway Institute, Fenway Health, Boston, MA, USA; Department of Medicine, Beth Israel Deaconess Medical Centre/Harvard Medical School, Boston, MA, USA.

Publikováno v: The lancet. HIV [Lancet HIV] 2024 Aug; Vol. 11 (8), pp. e508-e521. Date of Electronic Publication: 2024 Jul 14.

Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.

Autor: Lawitz EJ; Texas Liver Institute and University of Texas Health, San Antonio, Texas., Bhandari BR; Delta Research Partners, LLC, Bastrop, Louisiana., Ruane PJ; Ruane Clinical Research Group, Inc, Los Angeles, California., Kohli A; Arizona Liver Health, Chandler, Arizona., Harting E; Gilead Sciences, Inc, Foster City, California., Ding D; Gilead Sciences, Inc, Foster City, California., Chuang JC; Gilead Sciences, Inc, Foster City, California., Huss RS; Gilead Sciences, Inc, Foster City, California., Chung C; Gilead Sciences, Inc, Foster City, California., Myers RP; Gilead Sciences, Inc, Foster City, California., Loomba R; UC San Diego, La Jolla, California. Electronic address: roloomba@ucsd.edu.

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2023 Jan; Vol. 21 (1), pp. 143-152.e3. Date of Electronic Publication: 2022 Jan 06.